title: Response to: Are all non-thymidine analogue backbones appropriate for treating antiretroviral-naïve patients?
authors.forename: C
authors.initials: C
authors.lastname: Brothers
authors.forename: A
authors.initials: A
authors.lastname: Cutrell
authors.forename: T
authors.initials: T
authors.lastname: Scott
authors.forename: J
authors.initials: J
authors.lastname: Hernandez
authors.forename: A
authors.initials: A
authors.lastname: Moult
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects*; D015224:Dideoxynucleosides / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects*; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D018894:Reverse Transcriptase Inhibitors; D000099227:Abacavir